Back to News
Market Impact: 0.35
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
Source: zacks.com
Corporate EarningsAnalyst EstimatesCorporate Guidance & OutlookHealthcare & BiotechCompany Fundamentals
Harmony Biosciences missed Q3 earnings estimates as higher costs weighed on profits. Wakix demand and pipeline progress supported the company’s 2026 revenue outlook, tempering the negative earnings result.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.15
Ticker Sentiment
HRMY-0.35
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- How to Automate Equity Research Workflows: A Control-First Guide
- Weekly Update: Advanced Search Filters, Redesigned Ticker Dashboard, and Improved Search Experience